STAT3 gene polymorphisms and susceptibility to non-small cell lung cancer
STAT3 gene polymorphisms and susceptibility to non-small cell lung cancer
复制标题
STAT3基因多态性与非小细胞肺癌易感性
DOI：
10.4238/vol10-3gmr1071
复制
发表时间：
2011-01-01
影响因子：
0.4
通讯作者：
Huang, G.
中科院分区：
文献类型：
--
作者：
Jiang, B.;Zhu, Z. Z.;Huang, G.
信号转导和转录激活蛋白3（STAT 3）与癌症的发生有关，被认为是一种致癌基因。然而，STAT 3基因单核苷酸多态性（SNP）与癌症风险的关联研究很少，也不适用于肺癌。我们研究了STAT 3多态性是否与非小细胞肺癌（NSCLC）的风险相关。采用TaqMan技术对326例NSCLC患者和432例对照者的STAT 3基因的8个SNPs进行基因分型。观察到次要等位基因rs 4796793携带者的NSCLC风险显著降低（比值比（OR）= 0.68，95%置信区间（CI）= 0.51-0.92），rs7211777（OR = 0.67，95%CI = 0.50-0.90），rs12949918（OR = 0.73，95%CI = 0.54-0.97），rs744166（OR = 0.69，95%CI = 0.51-0.92）、rs9912773（OR = 0.75，95%CI = 0.55-0.98）和rs3869550（OR = 0.70，95%CI = 0.53-0.94）。GGCGGC单倍型由6个NSCLC相关SNP的次要等位基因组成，与最常见的CATACT单倍型相比，其NSCLC风险显著降低0.78倍（95%CI = 0.62-0.97）。按临床分期分层分析显示，STAT 3多态性与NSCLC风险之间的相关性趋势在I/II期和III/IV期均存在，并且在III/IV期表现出中等强度。我们的结论是，STAT 3基因多态性可能在非小细胞肺癌的发展，特别是III/IV期非小细胞肺癌的保护作用。
Signal transducer and activator of transcription protein 3 (STAT3) has been implicated in cancer development and is recognized as a type of oncogene. However, association studies of single nucleotide polymorphisms (SNPs) in the STAT3 gene with cancer risk are rare and not available for lung cancer. We examined whether STAT3 polymorphisms are associated with the risk of non-small cell lung cancer (NSCLC). Eight SNPs in the STAT3 gene were genotyped by TaqMan assays in 326 NSCLC cases and 432 controls in a Chinese population. Significant decreased risk of NSCLC was observed for carriers of minor alleles rs4796793 (odds ratio (OR) = 0.68, 95% confidence interval (CI) = 0.51-0.92), rs7211777 (OR = 0.67, 95%CI = 0.50-0.90), rs12949918 (OR = 0.73, 95%CI = 0.54-0.97), rs744166 (OR = 0.69, 95%CI = 0.51-0.92), rs9912773 (OR = 0.75, 95%CI = 0.55-0.98), and rs3869550 (OR = 0.70, 95%CI = 0.53-0.94). The GGCGGC haplotype, comprised of minor alleles of the six NSCLC-associated SNPs, had a 0.78-fold (95%CI = 0.62-0.97) significantly decreased risk of NSCLC, as compared to the most common haplotype of CATACT. Stratification analyses by clinical stage showed that the trend for the association between STAT3 polymorphisms and NSCLC risk was present both for stage I/II and stage III/IV, and appeared moderately stronger for stage III/IV. We conclude that polymorphisms in the STAT3 gene may have a protective role in the development of NSCLC, particular of stage III/IV NSCLC.